Psyence BioMed Exports 1mg and 5mg GMP Psilocybin Capsules for 87-Patient Phase IIb Trial
Psyence BioMed shipped GMP-compliant NPX-5 capsules (1mg and 5mg) from its PsyLabs facility to Australia, supporting its Phase IIb trial for Adjustment Disorder in 87 palliative cancer patients across Melbourne and Perth. This export validates the company’s vertically integrated, globally regulated supply chain for natural psilocybin therapeutics.
1. Export Milestone
Psyence BioMed completed the export of GMP-manufactured NPX-5 capsules (1mg and 5mg) from its PsyLabs facility to Australia, securing international regulatory authorization and demonstrating operational readiness for global shipments.
2. Phase IIb Trial Details
The NPX-5 shipment supports the ongoing double-blind, randomized, low-dose comparator-controlled Phase IIb trial in Australia, enrolling 87 cancer patients with Adjustment Disorder at multiple centers in Melbourne and Perth, with patient dosing initiated in late 2025.
3. Manufacturing and Supply Chain
PsyLabs operates a fully GMP-compliant production and analytical facility enabling vertical integration across cultivation, extraction, manufacturing, and quality assurance, reinforcing Psyence BioMed's ability to supply pharmaceutical-grade natural psilocybin at scale.
4. Strategic Significance
This export validates Psyence BioMed’s regulated global supply chain strategy and operational discipline, positioning the company as a leader in nature-derived psychedelic therapeutics and potentially enhancing its competitive differentiation and valuation.